Thyroid Nodule Biopsy Thresholds

Order a dedicated thyroid ultrasound to characterize each clinically relevant nodule and apply an established sonographic risk-stratification system before FNA. Ultrasound is the imaging method of choice, and both sonographic appearance and size determine whether biopsy is indicated. thyroid+2thyroidVol 11 Issue 9 p.7-8 | American Thyroid AssociationthyroidVol 11 Issue 9 p.5-6 | American Thyroid Associationnice org ukRecommendations | Thyroid cancer: assessment and management | Guidance | NICE

Use ACR TI-RADS when its scoring framework is available because it standardizes ultrasound-based biopsy selection and is associated with fewer recommended biopsies than ATA-based recommendations in a comparative analysis. In that study, the unnecessary-FNA rate was 26.3% with ACR TI-RADS versus 47.4% with ATA criteria; this tradeoff favors avoiding biopsy of low-yield nodules while requiring reliable sonographic categorization. ScienceDirect+1ScienceDirectComparison of thyroid nodule FNA rates recommended by ACR TI-RADS, Kwak TI-RADS and ATA guidelinesthyroidVol 11 Issue 9 p.5-6 | American Thyroid Association

For an ACR TI-RADS TR3 nodule, consider ultrasound-guided FNA only when the maximum diameter is at least 2.5 cm. A TR3 designation carries low malignancy risk, so biopsy below this threshold is generally not supported by the ACR threshold cited here. JAMAJAMAACR TI-RADS Classification and Bethesda Scoring of Thyroid Nodules

Do not equate a subcentimeter nodule with an automatic FNA indication. The 2015 ATA guidance cited in the literature does not recommend further evaluation for nodules smaller than 1 cm, and TI-RADS has been validated as a malignancy-risk approach even among nodules 1 cm or smaller. JAMA+1JAMAMachine Learning by Ultrasonography for Genetic Risk StratificationthyroidVol 11 Issue 9 p.7-8 | American Thyroid Association

When ultrasound grading alone does not meet an FNA threshold but the clinician identifies another reason for concern, choose between FNAC and active surveillance rather than disregarding the discordant concern. This is a risk-based exception, not a mandate to biopsy every small lesion. nice org uknice org ukRecommendations | Thyroid cancer: assessment and management | Guidance | NICE

Clinical factors historically associated with higher concern include childhood head and neck irradiation and family history of thyroid cancer; an older guidance excerpt describes consideration of ultrasound-guided FNA for nodules larger than 5 mm in such patients but also notes lack of supporting data for that universal approach. Use these factors to intensify ultrasound review and individualized decision-making rather than applying a blanket 5-mm biopsy rule. WHOWHO[PDF] PHC ENG GUIDE 200 - Extranet Systems

Perform thyroid FNA under ultrasound guidance when biopsy is selected. FNA is described as the gold-standard evaluation for thyroid nodules and detection of nodal metastasis, is usually outpatient, and is minimally invasive and safe. Wiley+2WileyBusiness of Medicine/Practice ManagementWileyFate of nondiagnostic thyroid fine needle aspirations - Storozuk - 2024pubs rsnaUS-guided Fine-Needle Aspiration of Thyroid Nodules

Request cytology reported using the Bethesda System because the central output of FNA is malignancy-risk classification, not simply a benign-versus-cancer label. FNA accurately classifies most nodules as benign and a smaller proportion as malignant, but indeterminate results remain common and require a separate management branch. JAMA+1JAMAPerformance of a Multigene Genomic Classifier in Thyroid Nodules ...thyroidThyroid Health – Molecular testing in thyroid nodules: it is all about risk of malignancy | American Thyroid Association

Treat a nondiagnostic specimen as an inadequate decision point, particularly if ultrasound remains suspicious. Nondiagnostic and indeterminate cytology are among the cytologic situations in which repeat FNA, molecular testing, diagnostic hemithyroidectomy, or surveillance may be considered according to the imaging-risk context. nice org uk+2nice org uk[PDF] NG230 Thyroid cancer: assessment and management - NICEpubs rsnaThyroid Nodules with Initially Nondiagnostic Cytologic ResultsPubMedManagement of thyroid nodules with indeterminate fine-needle aspiration cytology: histogram analysis of greyscale sonograms and molecular assay of residual tissue from fine-needle aspiration biopsies - PMC

For Bethesda III atypia of undetermined significance/follicular lesion of undetermined significance, repeat ultrasound-guided FNA is a reasonable first strategy when immediate surgery is not otherwise indicated. In a 2025 comparative study, repeat FNA produced benign cytology in 48.7% and persistent AUS in 35.9% of cases; surgery and malignancy rates did not significantly differ from molecular-testing-first management, while repeat FNA had the lowest diagnostic cost by Medicare reimbursement rates. ScienceDirectScienceDirectManaging TBSRTC III thyroid nodules: evaluating repeat FNA, molecular testing, and surgery

Use molecular testing as a risk-stratification adjunct for AUS/FLUS or suspicious-for-follicular-neoplasm cytology when the result will change the decision between surveillance and diagnostic surgery. Molecular testing can estimate malignancy likelihood and identify tumor phenotypes, but no current molecular test definitively diagnoses malignancy in every indeterminate nodule. ScienceDirect+2ScienceDirectMolecular Profiling for Bethesda III to VI Nodules - ScienceDirect.comthyroidThyroid Health – Molecular testing in thyroid nodules: it is all about risk of malignancy | American Thyroid AssociationPubMedManagement of thyroid nodules with indeterminate fine-needle aspiration cytology: histogram analysis of greyscale sonograms and molecular assay of residual tissue from fine-needle aspiration biopsies - PMC

Give ultrasound discordance decisive weight. Among AUS/FLUS nodules in one study, reported malignancy rates were 7.7% for sonographically benign or very-low-risk nodules, 58% for low- or intermediate-suspicion nodules, and 100% for high-suspicion nodules. A high-suspicion ultrasound result with indeterminate cytology should therefore trigger repeat ultrasound-guided FNA or molecular testing and may support diagnostic resection if uncertainty persists. PubMedPubMedManagement of thyroid nodules with indeterminate fine-needle aspiration cytology: histogram analysis of greyscale sonograms and molecular assay of residual tissue from fine-needle aspiration biopsies - PMC

Do not manage Bethesda III and Bethesda IV as interchangeable categories. Bethesda IV nodules had higher cancer risk than Bethesda III nodules even with a negative molecular test in a reported follow-up cohort; a negative molecular result should be interpreted with the cytology category and ultrasound pattern rather than used as an isolated rule-out test. thyroidthyroidVol 18 Issue 7 p.11-12 | American Thyroid Association

For benign nodules, periodic ultrasound monitoring is an appropriate nonoperative pathway. Benign nodules generally do not require treatment, and ultrasound surveillance is recommended rather than routine intervention. WHOWHO[PDF] PHC ENG GUIDE 200 - Extranet Systems

Repeat FNA is most defensible when the prior cytology is benign or nondiagnostic but the ultrasound or clinical assessment remains concerning. This escalation is driven by imaging–cytology mismatch, not by the mere existence of a benign nodule. nice org uk+1nice org uk[PDF] NG230 Thyroid cancer: assessment and management - NICEPubMedManagement of thyroid nodules with indeterminate fine-needle aspiration cytology: histogram analysis of greyscale sonograms and molecular assay of residual tissue from fine-needle aspiration biopsies - PMC

For patients managed with active surveillance, periodic appointments including ultrasound and blood tests are part of the surveillance construct; the duration and frequency should be individualized to patient risk. nice org uknice org ukRecommendations | Thyroid cancer: assessment and management | Guidance | NICE